(Q33425421)

26 July 2017

title

Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions (English)

1 reference

26 July 2017

0 references

1

Diana Karpman

1 reference

26 July 2017

Anne-lie Ståhl

2

1 reference

26 July 2017

Ida Arvidsson

3

1 reference

26 July 2017

Karl Johansson

4

1 reference

26 July 2017

Sebastian Loos

5

1 reference

26 July 2017

Ramesh Tati

6

1 reference

26 July 2017

Zivile Békássy

7

1 reference

26 July 2017

Ann-Charlotte Kristoffersson

8

1 reference

26 July 2017

Maria Mossberg

9

1 reference

26 July 2017

Robin Kahn

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Advances in Experimental Medicine and Biology

26 July 2017

published in

1 reference

26 July 2017

volume

865

1 reference

26 July 2017

page(s)

19-42

1 reference

Complement. First of two parts

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Receptors, rafts, and microvesicles in thrombosis and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement and complement regulatory proteins as potential molecular targets for vascular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The contact/kinin and complement systems in vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cross-talk between the complement and the kinin system in vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement-mediated regulation of tissue factor activity in endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cellular mechanisms underlying the formation of circulating microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Ectocytosis caused by sublytic autologous complement attack on human neutrophils. The sorting of endogenous plasma-membrane proteins and lipids into shed vesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial activation and circulating markers of endothelial activation in kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microvesicles and viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microparticles: protagonists of a novel communication network for intercellular information exchange

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Leukocyte-derived microparticles in vascular homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Red blood cell microparticles: clinical relevance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles in diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Highlights of a new type of intercellular communication: microvesicle-based information transfer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Modulation of monocyte-endothelial cell interactions by platelet microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The many faces of endothelial microparticles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Regulation of transbilayer plasma membrane phospholipid asymmetry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microparticles in hemostasis and thrombosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Role of microparticles in atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microthrombocytosis and Platelet Fragmentation Associated with Idiopathic/Autoimmune Thrombocytopenic Purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial and platelet microparticles in vasculitis of the young.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Specific Interaction of Escherichia coli 0157:H7-Derived Shiga-like Toxin II with Human Renal Endothelial Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet activation in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Experimental studies on the hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Hemolytic uremic syndrome in children: platelet aggregation and membrane glycoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet activation leads to activation and propagation of the complement system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Studies on the binding of complement factor C4 in human platelets. Complement activation by means of cold agglutinins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Activation of human platelets through gp140, the C3d/EBV receptor (CR2)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human platelet-initiated formation and uptake of the C5-9 complex of human complement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human platelet activation by C3a and C3a des-arg

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Identification of a third component of complement-binding glycoprotein of human platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Factor H binds to washed human platelets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet-associated complement factor H in healthy persons and patients with atypical HUS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Association of alternative complement pathway components with human blood platelets: secretion and localization of factor D and beta 1H Globulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement and the atypical hemolytic uremic syndrome in children.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement factor H related proteins in immune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The development of atypical hemolytic uremic syndrome depends on complement C5

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation in thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombotic Thrombocytopenic Purpura with C′3Vascular Deposits: Report of a Case

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The interaction between factor H and Von Willebrand factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human complement factor H is a reductase for large soluble von Willebrand factor multimers--brief report

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles and the diagnosis of the vasculitides

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Diagnostic role of endothelial microparticles in vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab in severe Shiga-toxin-associated HUS

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Progress and Trends in Complement Therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

10.1007/978-3-319-18603-0_2

31 March 2020

Identifiers

DOI

1 reference

26 July 2017

1 reference